Pernobon Injection (Polynate Calcium)

Adult dosage

1. Methotrexate conventional therapy: Administer Polynate at 6-12mg intramuscularly every 6 hours, 4 times a day. 2. Methotrexate-Polynate rescue therapy: Starting from 3 hours after stopping methotrexate, administer 15mg of Polynate intravenously every 3 hours for a total of 9 doses, followed by 8 doses intravenously or intramuscularly every 6 hours. 3. Use in progressive colon cancer with 5-Fluorouracil (5-FU)

This medication is not suitable for the treatment of pernicious anemia due to vitamin B12 deficiency or other megaloblastic anemias. Care is needed as hematologic status may improve while neurological symptoms progress. When using the injection, glass fragments may be introduced when cutting the ampoule, so care must be taken to ensure that no glass particles enter, especially when administering to children or the elderly. Certain cases of pregnant or breastfeeding women should avoid this medication, especially when used in combination with 5-FU. Caution is also warranted for women of childbearing potential or nursing mothers. This medication may cause allergic reactions such as urticaria or anaphylaxis, so immediate consultation with healthcare personnel is necessary if unusual symptoms occur. Pain at the injection site may occur, and symptoms such as fever or neurological disturbances may also develop. This medication reduces toxicity when used in combination with the anticancer drug methotrexate, so regular monitoring of blood methotrexate levels is required to determine the duration of therapy and dosage. If renal function is impaired or body fluid status is abnormal, drug clearance may be delayed, necessitating dosage adjustments. This medication shares transporters with methotrexate; hence, if there is resistance to methotrexate, there may also be resistance to this drug. If severe vomiting or difficulty in drug absorption occurs, administering it as an injection is preferable. When used with 5-FU, this medication may increase the effects and side effects of 5-FU, thus requiring frequent blood tests and liver function tests, with dosage adjustments of 5-FU if adverse reactions are significant. Additionally, this medication can lower the serum concentrations of drugs such as phenobarbital, phenytoin, and primidone, increasing the risk of seizures; thus, monitoring serum levels and adjusting doses are necessary. This medication contains calcium, so care must be taken not to exceed an intravenous administration rate of 160mg per minute, and intrathecal administration is prohibited. Store this medication out of the reach of children, sealing it in its original container, as transferring it to another container may lead to misuse or degradation of quality. Elderly patients may have altered responses due to decreased physiological function, so special caution is required during administration.

Serious side effects

Urticaria, anaphylactic reactions

Mild side effects

• Vascular pain
• transient pain
• fever
• agitation
• depression
• diarrhea
• skin reactions
• skin dryness
• stomatitis
• conjunctivitis

This medication is sensitive to light and should be stored in a sealed container that blocks light. Additionally, it is best to store the medication at room temperature in a place that is not too hot or too cold.

Appearance

Colorless to light yellow transparent injection solution in brown ampoules

Package unit

1mL-50 ampoules per box